Latest News
-
Tuesday - July 2, 2019
Data-Driven Tools from The Climate Corporation’s Climate FieldView™ Platform Now Available for Argentine Farmers:
Bayer expands industry-leading digital farming platform in Argentina » more
-
Tuesday - July 2, 2019
LEO Pharma completes the acquisition of Bayer’s prescription dermatology business » more
-
Monday - July 1, 2019
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies / Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments » more
-
Wednesday - June 26, 2019
Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg as mediator » more
-
Wednesday - June 26, 2019
Not intended for U.S. and UK Media
Bayer will present new data on its hemophilia treatments at ISTH 2019 » more
-
Monday - June 24, 2019
Helping growers worldwide to control major pests:
Bayer and AlphaBio Control sign distribution agreement for innovative biological pest control product » more
-
Friday - June 21, 2019
Not intended for U.S. and UK Media
Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infants » more
-
Wednesday - June 19, 2019
Not intended for U.S. and UK Media
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
GBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results from the Phase II REGOMA study (Lombardi G et al, Lancet Oncol, 2018) support further evaluation of regorafenib in patients with newly diagnosed and recurrent glioblastoma, the most aggressive form of brain cancer / Medical need remains high in glioblastoma as treatment options are limited and patient outcomes have remained largely unchanged over several decades » more
-
Friday - June 14, 2019
Bayer raises the bar in transparency, sustainability and engagement
With its solutions, the company aims to reduce environmental impact by 30 percent / Approximately 5 billion euros will be invested in additional methods to combat weeds over the next decade / Invitation to scientists, journalists and NGO representatives to participate in the scientific preparation for the upcoming EU glyphosate re-registration process / Crop protection products will only be sold in developing countries if they meet the standards of a majority of leading regulators on top of local regulations » more
-
Wednesday - June 5, 2019
Bayer at the ISF World Seed Congress 2019 in Nice, France:
Shaping agriculture through new seed varieties and innovative seed-applied technologies
Innovation and technologies make agriculture more productive and sustainable / NemaStrike™ Technology helps corn, soybean, and cotton farmers protect their yield / Bayer expands biological seed treatment portfolio with JumpStart™ and ProStablish™ » more
-
Tuesday - June 4, 2019
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Agreement worth more than USD 110 million includes the first-ever research application of Proteolysis-Targeting Chimera (PROTAC®) technology in agriculture / Bayer and Arvinas to launch joint venture to develop targeted protein degraders for agriculture applications / Collaboration agreement and equity investment by Bayer to develop next-generation medicines for patients with cardiovascular, oncological and gynecological diseases » more
-
Monday - June 3, 2019
Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:
New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019
In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients / In 14 adult and pediatric patients with TRK fusion cancer with primary central nervous system (CNS) tumors (including high grade gliomas), the overall response rate was 36% including two complete responses / 71% of evaluable patients with primary CNS tumors experienced disease control for 24 weeks or more / First prospective analysis of the activity of larotrectinib in patients with TRK fusion cancer and intracranial disease, including first data ever presented for a TRK inhibitor in adult primary CNS TRK fusion cancer » more
-
Friday - May 31, 2019
Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Bayer’s darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate cancer
Results of a new post-hoc analysis showed that treatment with darolutamide plus androgen deprivation therapy (ADT) delayed worsening of urinary and bowel symptoms versus placebo plus ADT / Exposure-adjusted incidences of treatment-emergent adverse events (TEAEs), including notably TEAEs associated with androgen receptor (AR) antagonists, were generally similar for darolutamide plus ADT compared to placebo plus ADT / Darolutamide plus ADT maintained quality of life in men with non-metastatic castration-resistant prostate cancer (nmCRPC) beyond end of study treatment with scores similar to placebo plus ADT / Analysis on quality of life related endpoints from pivotal Phase III ARAMIS trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation on May 31, 2019 / Darolutamide is under Priority Review in the U.S., and has been filed in Europe, Japan and additional countries » more
-
Wednesday - May 29, 2019
Not intended for U.S. and UK Media
Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics (CDx) in oncology
Collaboration will start with development of a companion diagnostic for larotrectinib, the first and only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors; larotrectinib is under review in other markets around the world / Goal is to advance broad patient access to comprehensive genomic testing in line with Bayer’s commitment to precision medicine » more
-
Wednesday - May 29, 2019
Not intended for U.S. and UK Media
Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma
U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib primarily based on follow-up data from the pivotal Phase II study CHRONOS-1, which showed the efficacy of copanlisib in patients with indolent non-Hodgkin’s lymphoma (iNHL) who have received at least two prior therapies, including patients with relapsed or refractory marginal zone lymphoma (MZL) / Breakthrough Designation aims to facilitate the timely development and review of new treatment options for patients with high unmet medical need / Bayer is conducting two additional Phase III studies – CHRONOS-3 and CHRONOS-4 – to confirm the efficacy and safety of copanlisib in combination with other therapies in iNHL (including MZL) patients who have relapsed following one or more prior therapies » more
-
Tuesday - May 28, 2019
100 new young leaders join the journey towards Zero Hunger
The biennial Bayer Youth Ag Summit brings together 100 young food security activists to develop concrete projects to help feed a hungry planet / The 2019 Summit will take place from 4-6 November in Brasilia, Brazil / Bayer received over 2,800 applications from more than 140 countries » more
-
Thursday - May 23, 2019
Not intended for U.S. and UK Media
Bayer announces 5-year partnership with the World Federation of Hemophilia Humanitarian Aid Program
The donation of Factor VIII treatments will support as many as 5,000 people living with hemophilia A in countries with insufficient access to care / Partnership involves a 50 million international units donation of Factor VIII treatment in 2019 / Program supports training, education and delivery of FVIII treatments to healthcare professionals in over 60 countries » more
-
Friday - May 17, 2019
Bayer is a main sponsor of the IUPAC International Congress of Crop Protection in Belgium:
Industry experts and scientists will discuss strategies for future weed, disease and pest control in agriculture » more
-
Wednesday - May 15, 2019
Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases
In children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) not reached / In adults with TRK fusion cancer (n=74), the ORR was 76% and durable, with median DOR not reached / In evaluable patients with brain metastases (n=5), ORR was 60% / Improvements in quality of life were shown with larotrectinib treatment in both children and adults / Majority of adverse events were grade 1 or 2, as reported in prior publications » more
-
Monday - May 13, 2019
Bayer statement on jury’s decision in California State Glyphosate Trial » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 25, 2021
Financial News Conference on the Full Year 2020 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV